Recent Progress in Modulation of WD40-Repeat Domain 5 Protein (WDR5): Inhibitors and Degraders

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Aug 12

PMID 37568727

Authors

Raju Gurung

Darlami Om

Rabin Pun

Soonsil Hyun

Dongyun Shin

Affiliations

Soon will be listed here.

Abstract

WD40-repeat (WDR) domain proteins play a crucial role in mediating protein-protein interactions that sustain oncogenesis in human cancers. One prominent example is the interaction between the transcription factor MYC and its chromatin co-factor, WD40-repeat domain protein 5 (WDR5), which is essential for oncogenic processes. The MYC family of proteins is frequently overexpressed in various cancers and has been validated as a promising target for anticancer therapies. The recruitment of MYC to chromatin is facilitated by WDR5, highlighting the significance of their interaction. Consequently, inhibiting the MYC-WDR5 interaction has been shown to induce the regression of malignant tumors, offering an alternative approach to targeting MYC in the development of anticancer drugs. WDR5 has two protein interaction sites, the "WDR5-binding motif" (WBM) site for MYC interaction and the histone methyltransferases SET1 recognition motif "WDR5-interacting" (WIN) site forming MLL complex. Significant efforts have been dedicated to the discovery of inhibitors that target the WDR5 protein. More recently, the successful application of targeted protein degradation technology has enabled the removal of WDR5. This breakthrough has opened up new avenues for inhibiting the interaction between WDR5 and the binding partners. In this review, we address the recent progress made in targeting WDR5 to inhibit MDR5-MYC and MDR5-MLL1 interactions, including its targeted protein degradation and their potential impact on anticancer drug discovery.

Citing Articles

A Target Class Ligandability Evaluation of WD40 Repeat-Containing Proteins.

Ackloo S, Li F, Szewczyk M, Seitova A, Loppnau P, Zeng H J Med Chem. 2024; 68(2):1092-1112.

PMID: 39495097 PMC: 11770632. DOI: 10.1021/acs.jmedchem.4c02010.

Quantitative Hydrogen-Deuterium Exchange Mass Spectrometry for Simultaneous Structural Characterization and Affinity Indexing of Single Target Drug Candidate Libraries.

Wolf E, Herasymenko O, Kutera M, Lento C, Arrowsmith C, Ackloo S Anal Chem. 2024; 96(32):13015-13024.

PMID: 39074309 PMC: 11326436. DOI: 10.1021/acs.analchem.4c01001.

Genome-Wide Identification, Evolution, and Expression Analysis of the WD40 Subfamily in Genus.

Ke S, Jiang Y, Zhou M, Li Y Int J Mol Sci. 2023; 24(21).

PMID: 37958759 PMC: 10648978. DOI: 10.3390/ijms242115776.

References

Southall S, Wong P, Odho Z, Roe S, Wilson J . Structural basis for the requirement of additional factors for MLL1 SET domain activity and recognition of epigenetic marks. Mol Cell. 2009; 33(2):181-91. DOI: 10.1016/j.molcel.2008.12.029. View

Zhu J, Sammons M, Donahue G, Dou Z, Vedadi M, Getlik M . Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature. 2015; 525(7568):206-11. PMC: 4568559. DOI: 10.1038/nature15251. View

Grebien F, Vedadi M, Getlik M, Giambruno R, Grover A, Avellino R . Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia. Nat Chem Biol. 2015; 11(8):571-578. PMC: 4511833. DOI: 10.1038/nchembio.1859. View

Senisterra G, Wu H, Allali-Hassani A, Wasney G, Barsyte-Lovejoy D, Dombrovski L . Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5. Biochem J. 2012; 449(1):151-9. PMC: 3517986. DOI: 10.1042/BJ20121280. View

Karatas H, Townsend E, Cao F, Chen Y, Bernard D, Liu L . High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction. J Am Chem Soc. 2012; 135(2):669-82. PMC: 5180416. DOI: 10.1021/ja306028q. View

Chen X, Xu J, Wang X, Long G, You Q, Guo X . Targeting WD Repeat-Containing Protein 5 (WDR5): A Medicinal Chemistry Perspective. J Med Chem. 2021; 64(15):10537-10556. DOI: 10.1021/acs.jmedchem.1c00037. View

Getlik M, Smil D, Zepeda-Velazquez C, Bolshan Y, Poda G, Wu H . Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1). J Med Chem. 2016; 59(6):2478-96. DOI: 10.1021/acs.jmedchem.5b01630. View

Thomas L, Wang Q, Grieb B, Phan J, Foshage A, Sun Q . Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC. Mol Cell. 2015; 58(3):440-52. PMC: 4427524. DOI: 10.1016/j.molcel.2015.02.028. View

Thomas L, Foshage A, Weissmiller A, Tansey W . The MYC-WDR5 Nexus and Cancer. Cancer Res. 2015; 75(19):4012-5. PMC: 4592407. DOI: 10.1158/0008-5472.CAN-15-1216. View

10.

Chen W, Chen X, Li D, Wang X, Long G, Jiang Z . Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity. Eur J Med Chem. 2021; 223:113677. DOI: 10.1016/j.ejmech.2021.113677. View

11.

Chen W, Chen X, Li D, Zhou J, Jiang Z, You Q . Discovery of as a Potent and Orally Bioavailable Inhibitor of the WDR5-Mixed Lineage Leukemia 1 Protein-Protein Interaction for the Treatment of MLL Fusion Leukemia. J Med Chem. 2021; 64(12):8221-8245. DOI: 10.1021/acs.jmedchem.1c00091. View

12.

Karatas H, Li Y, Liu L, Ji J, Lee S, Chen Y . Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia (MLL) Protein-Protein Interaction. J Med Chem. 2017; 60(12):4818-4839. DOI: 10.1021/acs.jmedchem.6b01796. View

13.

Thomas L, Adams C, Wang J, Weissmiller A, Creighton J, Lorey S . Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance. Proc Natl Acad Sci U S A. 2019; 116(50):25260-25268. PMC: 6911241. DOI: 10.1073/pnas.1910391116. View

14.

Xie Q, Li Z, Chen J . WDR5 positively regulates p53 stability by inhibiting p53 ubiquitination. Biochem Biophys Res Commun. 2017; 487(2):333-338. DOI: 10.1016/j.bbrc.2017.04.060. View

15.

Namitz K, Tan S, Cosgrove M . Hierarchical assembly of the MLL1 core complex regulates H3K4 methylation and is dependent on temperature and component concentration. J Biol Chem. 2023; 299(2):102874. PMC: 9939731. DOI: 10.1016/j.jbc.2023.102874. View

16.

Teuscher K, Chowdhury S, Meyers K, Tian J, Sai J, Van Meveren M . Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models. Proc Natl Acad Sci U S A. 2022; 120(1):e2211297120. PMC: 9910433. DOI: 10.1073/pnas.2211297120. View

17.

Sun Y, Bell J, Carter D, Gherardi S, Poulos R, Milazzo G . WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma. Cancer Res. 2015; 75(23):5143-54. DOI: 10.1158/0008-5472.CAN-15-0423. View

18.

Zhang J, Zhou Q, Xie K, Cheng L, Peng S, Xie R . Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer. J Exp Clin Cancer Res. 2021; 40(1):203. PMC: 8215817. DOI: 10.1186/s13046-021-01989-5. View

19.

Carugo A, Genovese G, Seth S, Nezi L, Rose J, Bossi D . In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Cell Rep. 2016; 16(1):133-147. DOI: 10.1016/j.celrep.2016.05.063. View

20.

Bekes M, Langley D, Crews C . PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022; 21(3):181-200. PMC: 8765495. DOI: 10.1038/s41573-021-00371-6. View